Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Argonaute/RNA-induced silencing complex (RISC) is a multi-protein ribonucleoprotein complex that plays a central role in post-transcriptional gene silencing via the RNA interference (RNAi) pathway. The core catalytic component of RISC is an Argonaute protein (primarily AGO2 in humans), which binds a single-stranded small RNA guide (such as a microRNA or small interfering RNA) to recognize and cleave complementary messenger RNA (mRNA) transcripts, or otherwise repress their translation. In its physiological state, the Argonaute/RISC complex regulates cellular homeostasis, development, and defense against viral infections by modulating gene expression. Dysregulation of endogenous RISC components or microRNA pathways is implicated in various diseases, including cancers, cardiovascular disorders, and genetic diseases.
In therapeutics, the Argonaute/RISC complex is co-opted by synthetic small interfering RNA (siRNA) drugs to achieve highly specific, long-lasting knockdown of disease-causing genes. Upon delivery into the cytoplasm, double-stranded siRNA drugs are loaded into the complex, where the passenger strand is discarded, and the guide strand directs AGO2 to cleave the target mRNA. This mechanism has been successfully leveraged by several FDA-approved therapeutics, such as patisiran, givosiran, lumasiran, inclisiran, vutrisiran, and nedosiran, to treat conditions ranging from hereditary transthyretin-mediated amyloidosis to hypercholesterolemia.
siRNA or miRNA loading into the RISC complex, followed by passenger strand cleavage/discarding, and guide strand-mediated complementary mRNA targeting and cleavage by Argonaute (specifically AGO2).
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Argonaute/RNA-induced silencing complex (RISC).